Cargando…

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma

OBJECTIVE: To investigate the effect of bicalutamide combined with docetaxel on the levels of prostate-specific antigen (PSA) in serum and vascular endothelial growth factor (VEGF) in patients with advanced prostate carcinoma (PCa). METHODS: The clinical data of 103 patients with advanced PCa at our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Zhaoxin, Hu, Xiaolin, Lv, Renguang, Zhang, Yongzhen, Meng, Liwei, Liu, Zhaoxu, Yan, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402358/ https://www.ncbi.nlm.nih.gov/pubmed/36033830 http://dx.doi.org/10.1155/2022/4506350

Ejemplares similares

Case report: An ectopic adrenocortical adenoma in the renal sinus
por: Liu, Tianyu, et al.
Publicado: (2022)

Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway
por: Guo, Zhaoxin, et al.
Publicado: (2015)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer
por: Kang, Yu Jin, et al.
Publicado: (2014)

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
por: Dijkstra, Siebren, et al.
Publicado: (2016)

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy
por: Bohr, Adam, et al.
Publicado: (2019)

A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure
por: Muramatsu, Tomoaki, et al.
Publicado: (2019)

Spectrophotometric Estimation of Bicalutamide in Tablets
por: Sancheti, P. P., et al.
Publicado: (2008)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
por: Kandil, Sahar B., et al.
Publicado: (2020)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
por: Tian, Lei, et al.
Publicado: (2022)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer
por: Johnson, Tamara Jane, et al.
Publicado: (2013)

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
por: Li, Yuezheng, et al.
Publicado: (2023)

Compression-Induced Phase Transitions of Bicalutamide
por: Szafraniec-Szczęsny, Joanna, et al.
Publicado: (2020)

Cysteamine–bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
por: Jamalpoor, Amer, et al.
Publicado: (2021)

Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis
por: Mahal, Brandon A., et al.
Publicado: (2023)

KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
por: Jha, Sawan Kumar, et al.
Publicado: (2019)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer
por: Fryczkowski, M., et al.
Publicado: (2018)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer
por: Mao, Zujie, et al.
Publicado: (2018)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis
por: Puri, Claudia, et al.
Publicado: (2009)

Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125
por: Wang, Ning, et al.
Publicado: (2022)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
por: Saito, Seiichi
Publicado: (2019)

Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016)

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy
por: Gasinska, Anna, et al.
Publicado: (2019)

Bicalutamide-induced hepatotoxicity: A rare adverse effect
por: Hussain, Salwa, et al.
Publicado: (2014)

Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia
por: Gomez-Zubiaur, Alba, et al.
Publicado: (2023)

Retracted: Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125
por: Healthcare Engineering, Journal of
Publicado: (2023)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer?
por: Lewis, R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_438vm8980cnmjq7492nci460cv